DLCS-ClearPath

ClearPath Development Company is a specialized drug development entity that utilizes a unique business model to accelerate the progression of clinical-stage assets. The company partners with major pharmaceutical firms, such as Astellas and Eli Lilly, to form dedicated subsidiaries focused on specific therapeutic areas or individual molecules. By leveraging a lean operating structure and externalized development expertise, ClearPath aims to de-risk early-stage programs and provide its partners with high-quality data for late-stage investment decisions. Their portfolio has historically included significant programs in cardiovascular health, infectious diseases, and immunology.